Sona Shah, MSc - Biomedical Engineering

Neopenda, PBC


Georgia Tech, Columbia University

About Me

Sona’s path to global health entrepreneurship began when she earned a BS in Chemical Engineering from Georgia Tech (2011), and subsequently worked as an engineer in Bioprocess Research and Development at Eli Lilly and Company. She followed her passion for service to Kenya, spending time as a teacher and a Engineering Without Borders volunteer. Sona’s interest in aiding under-resourced communities continued during her research involvement with mChip, a point-of-care diagnostic device for HIV and syphilis developed at Columbia University. She also worked at the TB Alliance, both in community engagement and drug discovery for medications that treat tuberculosis. Sona completed a Masters in Biomedical Engineering at Columbia University (2016) before launching Neopenda, where she develops works to develop impactful health care solutions, and sustainably deliver them to the world’s most vulnerable populations.

You have not backed any projects. Lets change that!
Discover Projects

No comments on any project yet. Lets change that!
Discover Projects

No likes on any project yet.. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No project reviewed yet. Lets change that!
Discover Projects

Important Disclosure: MedStartr.com is a website owned and operated by MedStartr, Inc., which is not a broker-dealer, funding portal or investment advisor; and neither the website nor MedStartr, Inc. participate in the offer or sale of securities. All securities related activity is conducted through Young America Capital, LLC, a registered broker-dealer and member of FINRA/SIPC. No communication, through this website, email or in any other medium, should be construed as a recommendation for any securities offering.